emergence agitation
Conditions
Interventions
Group A:0.1mg/kg nalbuphine
Group B:0.15 mg/kg nalbuphine
Group C:0.2 mg/kg nalbuphine
Group D:0.9% saline
Sponsors
the First Affiliated Hospital of the Air Force Medical University
Eligibility
Sex/Gender
All
Age
0.5 Years to 3 Years
Inclusion criteria
Inclusion criteria: 1. Aged 6 months to 3 years; 2. ASA grades I-II; 3. BW 5~15kg; 4. patients who intend to undergo cochlear implant surgery under general anesthesia; 5. Voluntary signing of informed consent.
Exclusion criteria
Exclusion criteria: 1. premature infants; 2. there is a state of airway hyperreaction such as upper respiratory tract infection before operation; 3. previous hypoxic ischemic encephalopathy with obvious sequelae; 4. congenital cardiac dysplasia with cardiac function > grade 3; 5. serious genetic diseases; 6. there are dysfunction of other important organs such as heart, brain, liver and kidney and abnormal blood coagulation before operation; 7. those who participated in other clinical trials in the three months before they were selected.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of emergence agitation; | — |
Secondary
| Measure | Time frame |
|---|---|
| time duration from drug withdrawal to extubation;nsufficient analgesia;Postoperative sedation;Side effects; | — |
Countries
China
Contacts
Public ContactZeng Yi
the First Affiliated Hospital of the Air Force Medical University
Outcome results
None listed